|
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo[R] in the United States.
Biotech Week
|
August 19, 2009
|
COPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
(Hide copyright information)
Copyright
|
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT) announced entry into an exclusive license and collaboration agreement to commercialize Intermezzo (zolpidem tartrate sublingual tablet) in the United States. If approved by the U.S. Food and Drug Administration (FDA), Intermezzo has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act ...
Find more facts and information related to the
article "Purdue Pharmaceutical Products L.P. and Transcept ..."